Product news

AstraZeneca announced that the FDA has approved Crestor (rosuvastatin calcium) as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol.

Bristol-Myers Squibb said the FDA has approved new labeling for Sprycel to include a lower recommended starting dose of 100 mg once daily and safety and efficacy data in a greater number of patients with chronic-phase chronic myeloid leukemia (CML) resistant or intolerant to prior therapy including Gleevec. The product labeling now also includes data from the first randomized trial of Sprycel and Gleevec. Sprycel is indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast-phase CML with resistance or intolerance to prior therapy including Gleevec.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.